[go: up one dir, main page]

WO2001008669A3 - Therapeutic agents for lymphoedema - Google Patents

Therapeutic agents for lymphoedema Download PDF

Info

Publication number
WO2001008669A3
WO2001008669A3 PCT/GB2000/002950 GB0002950W WO0108669A3 WO 2001008669 A3 WO2001008669 A3 WO 2001008669A3 GB 0002950 W GB0002950 W GB 0002950W WO 0108669 A3 WO0108669 A3 WO 0108669A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoedema
therapeutic agents
treatment
flk
kdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/002950
Other languages
French (fr)
Other versions
WO2001008669A2 (en
Inventor
David Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Priority to AU63023/00A priority Critical patent/AU6302300A/en
Publication of WO2001008669A2 publication Critical patent/WO2001008669A2/en
Anticipated expiration legal-status Critical
Publication of WO2001008669A3 publication Critical patent/WO2001008669A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The use of an agent which selectively inhibits, prevents or interferes with the signal transduced by flk-1/KDR when activated by a ligand, in the manufacture of a medicament for the treatment of lymphoedema and in a method for reducing the filtration rate from blood to tissue. Also provided is a method for identifying compounds useful in the treatment of lymphoedema, and compounds identified thereby.
PCT/GB2000/002950 1999-07-30 2000-07-31 Therapeutic agents for lymphoedema Ceased WO2001008669A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63023/00A AU6302300A (en) 1999-07-30 2000-07-31 Therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918057.2A GB9918057D0 (en) 1999-07-30 1999-07-30 Therapeutic agents
GB9918057.2 1999-07-30

Publications (2)

Publication Number Publication Date
WO2001008669A2 WO2001008669A2 (en) 2001-02-08
WO2001008669A3 true WO2001008669A3 (en) 2002-07-11

Family

ID=10858334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002950 Ceased WO2001008669A2 (en) 1999-07-30 2000-07-31 Therapeutic agents for lymphoedema

Country Status (3)

Country Link
AU (1) AU6302300A (en)
GB (1) GB9918057D0 (en)
WO (1) WO2001008669A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160180T1 (en) 2003-04-24 2016-03-25 Incyte Holdings Corp AZA SPIRO ALKANA DERIVATIVES AS METALOPROTEASE INHIBITORS

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
WO1994011499A1 (en) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 is a receptor for vascular endothelial growth factor
WO1995021613A1 (en) * 1994-02-09 1995-08-17 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1996040648A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
WO1996040675A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
WO1997009427A1 (en) * 1995-09-08 1997-03-13 Genentech, Inc. Vegf-related protein
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5766863A (en) * 1993-11-23 1998-06-16 Genentech, Inc. Kinase receptor activation assay
US5766860A (en) * 1992-11-23 1998-06-16 American Cyanamid Company Screening method using a recombinant kinase insert domain containing receptor and gene encoding same
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
WO1998039035A1 (en) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
WO1998055638A1 (en) * 1997-06-03 1998-12-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
WO1999010537A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
US5891650A (en) * 1993-11-23 1999-04-06 Genentech Incorporated Kinase receptor activation assay
WO1999017769A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
WO1999021859A1 (en) * 1997-10-10 1999-05-06 Glaxo Group Limited Azaoxindole derivatives
WO1999024440A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
WO2000058511A1 (en) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1994011499A1 (en) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 is a receptor for vascular endothelial growth factor
US5849742A (en) * 1992-11-13 1998-12-15 Sugen Inc. Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5766860A (en) * 1992-11-23 1998-06-16 American Cyanamid Company Screening method using a recombinant kinase insert domain containing receptor and gene encoding same
US5891650A (en) * 1993-11-23 1999-04-06 Genentech Incorporated Kinase receptor activation assay
US5766863A (en) * 1993-11-23 1998-06-16 Genentech, Inc. Kinase receptor activation assay
WO1995021613A1 (en) * 1994-02-09 1995-08-17 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
WO1996040648A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5891917A (en) * 1995-06-07 1999-04-06 Sugen, Inc. Certain acrylonitrile-sulfonamide derivatives
US5886195A (en) * 1995-06-07 1999-03-23 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1996040675A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
WO1997009427A1 (en) * 1995-09-08 1997-03-13 Genentech, Inc. Vegf-related protein
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
WO1998039035A1 (en) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
WO1998055638A1 (en) * 1997-06-03 1998-12-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
WO1999010537A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
WO1999017769A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
WO1999021859A1 (en) * 1997-10-10 1999-05-06 Glaxo Group Limited Azaoxindole derivatives
WO1999024440A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2000058511A1 (en) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
M.H.WITTE ET AL.: "PHENOTYPIC AND GENOTYPIC HETEROGENEITY IN FAMILIAL MILROY LYMPHEDEMA", LYMPHOLOGY, vol. 31, no. 4, December 1998 (1998-12-01), pages 145 - 155, XP000990600 *
M.J.KARKKAINEN ET AL.: "Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis", ONCOGENE, vol. 19, no. 49, 20 November 2000 (2000-11-20), pages 5598 - 5605, XP000990610 *
R.E.FERRELL ET AL.: "Hereditary lymphedema: evidence for linkage and genetic heterogeneity", HUMAN MOLECULAR GENETICS, vol. 7, no. 13, December 1998 (1998-12-01), pages 2073 - 2078, XP000990647 *
T. MÄKINEN ET AL.: "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3", NAT.MED., vol. 7, no. 2, February 2001 (2001-02-01), pages 199 - 205, XP000990590 *
V. JOUKOV ET AL.: "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases", THE EMBO JOURNAL, vol. 15, no. 2, 1996, pages 290 - 298, XP000100201 *
Y. CAO ET AL.: "Vascular endothelial growth factor C induces angiogenesis in vivo", PROC.NATL.ACAD.SCI. USA, vol. 95, no. 24, 24 November 1998 (1998-11-24), pages 14389 - 14394, XP000994696 *

Also Published As

Publication number Publication date
AU6302300A (en) 2001-02-19
GB9918057D0 (en) 1999-10-06
WO2001008669A2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
IL135712A0 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
WO2002058696A3 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
DE60204966D1 (en) Use of cyclopamine for the manufacture of a medicament for the treatment of psoriasis
CY1109191T1 (en) A NEW USE OF DIFFERIPRON
DE69116380D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
SE9101840D0 (en) NEW MEDICINAL USE
MY140626A (en) Drug screening methods and method of treatment
WO2001008669A3 (en) Therapeutic agents for lymphoedema
PL354961A1 (en) Prevention and treatment of diseases associated with blood coagulation
AU2003283227A8 (en) Method and means for the treatment of vascular and cardiac diseases
WO2003001877A3 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
IL150541A0 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
MXPA03000033A (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies.
NO995459D0 (en) Tissue factor for influencing blood vessel formation
WO2001022976A3 (en) Combination of a statin and ex-vivo treated blood for treating artheroclerosis
Neutel et al. P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension
AU2002225994A1 (en) Use of blood coagulation factor xiii for treating haemophilia
DE60122781D1 (en) NEW THERAPEUTIC USE OF A DERIVATIVE OF THIENYLCYCLOHEXYLAMINE FOR THE TREATMENT OF PAIN
RU97111211A (en) METHOD FOR TREATING PATIENTS WITH SURGICAL ENDOTOXICOSIS
EP1714661A3 (en) Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
Beckles et al. P-375: Attenuation of cardiac hypertrophy in vivo by interference with the jak/Stat pathway
HK1067298A1 (en) Pharmaceutical compositions of topic use, applied in treatment of skin and/or mucous injuries; use of compositions in treatment of skin and/or mucous injuries and use of compounds in treatment of skin and/or mucous injuries
WO2000050023A3 (en) Use of tamoxifen and related compounds as CLC3 blockers in the treatment of vascular diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP